MedTrace Logo

Gangwon PCI Prospective Registry

NCT02038127 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2024-07-24

No results posted yet for this study

Summary

Comparison of

* Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore
* Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott, USA
* Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent Medtronic, USA in patients with coronary artery disease treated with percutaneous coronary intervention

Conditions

Sponsors & Collaborators

  • Gangwon Cardiovascular Health Research Institute

    collaborator OTHER

  • Yonsei University

    lead OTHER

Principal Investigators

  • Junghan Yoon, M.D., Ph.D. · Yonsei University

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2030-12-31
Completion
2031-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038127 on ClinicalTrials.gov